Figures & data
Figure 1. The general chemical structure of a typical prenylated chalcone compound.
Figure 2. Effects of prenylated chalcone treatments on cell viability of C6, U87 MB, CNS-1 and 13-06 MB glioma cell lines. Data are the mean ± SD of triplicate analyses (n = 3). (*p < 0.05; **p < 0.01 versus control). 
5 μg/ml, 
10 μg/ml, 
15 μg/ml, 
20 μg/ml, 
25 μg/ml, 
30 μg/ml and 
40 μg/ml prenylated chalcone.
Figure 3. Effect of prenylated chalcone on cell cycle distribution of glioma cells. Data (% of cell in the indicated phase) are the mean ± SD of triplicate analysis (n = 3). 
25 μg/ml, 
30 μg/ml and 
35 μg/ml prenylated chalcone.
Figure 4. Fluorescence-activated cell sorter (FACS) analyses of apoptotic glioma cells. (A) Glioma cells treated with 15 and 30 μg/ml prenylated chalcone for 24 h. (B) Glioma cells treated with 30 μg/ml prenylated chalcone for 24, 36 and 48 h.
Figure 5. Apoptosis induced by prenylated chalcone treatment in glioma cells. (A) Chromatin condensation caused by 35 μg/ml prenylated chalcone at 24 h. (B) DNA fragmentation caused by 25, 30 and 35 μg/ml prenylated chalcone at 48 h. Marker: a 100-bp DNA ladder (left lane).
Figure 6. Effects of prenylated chalcone on apoptotic protein expression using western blotting. (A) Anti-proapoptosis (Bcl-2 and Bcl-XL) and anti-apoptosis (Bad and Bax) (B) PARP and anti-caspase 3. Glioma cells were treated with 25, 30 and 35 μg/ml prenylated chalcone.
Figure 7. Effect of prenylated chalcone on glioma cell migration using the scratch wound assay. Glioma cells were incubated with 30 μg/ml prenylated chalcone for 24 and 36 h. (A) C6, (B) U87 MB, (C) CNS-1 and (D) 13-06 MB.
